Orthofix launches new bioactive synthetic graft

Orthofix earned FDA 510(k) clearance for its OsteoCove advance bioactive synthetic graft, the company said Oct. 12.

Advertisement

The newly launched bone graft is available in putty and strip configurations, according to a news release. OsteoCove has a specialized granule surface topography for bone forming and is made of biphasic ceramic granule comprised of β-tricalcium phosphate and hydroxyapatitecombined with type-I bovine collagen.

“With the introduction of OsteoCove, we expect strong growth in this large market segment as we continue to deliver on our commitment to provide surgeons a comprehensive offering of biologic solutions to meet the needs of their patients,” Tyler Lipschultz, President of global biologics, said in the release.

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Biologics

  • Regenerative medicine company Auragens has opened an orthobiologics division.  Orthopedic surgeon Abdiel Ortiz, MD, will lead the new division, which…

  • So far this year, medtech companies and academic institutions are making key strides in spine biologics. From new product launches…

Advertisement

Comments are closed.